Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Clinical trial NCT05166772 · UNKNOWN
Trial details
- NCT number
- NCT05166772
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-01
- Primary completion
- 2023-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.